Funding for this research was provided by:
Vetenskapsrådet (521-2014- 2057)
Breast Cancer Research Foundation
National Research Foundation Singapore (NRF-NRFF2017-02)
Iris, Stig och Gerry Castenbäcks Stiftelsen
Swedish Cancer Society
Cancer Society in Stockholm Personalised Cancer Medicine
King Gustaf V Jubilee Foundation
Swedish Breast Cancer Association
NCI Breast SPORE program (P50-CA58223-09A1, R01- CA195754-01)
Konung Gustaf V:s Jubileumsfond
Text and Data Mining valid from 2019-02-28
Received: 5 December 2018
Accepted: 14 February 2019
First Online: 28 February 2019
Ethics approval and consent to participate
: Cohort 1 (METABRIC), publicly available data.Cohort 2, both gene expression and genotyping studies were approved by the ethics committee at Karolinska Institutet (Stockholm, Sweden).
: Not applicable
: JB receives research funding from Merck, paid to Karolinska Institutet and from Amgen, Roche, Sanofi-Aventis and Bayer and paid to Karolinska University Hospital. CMP is an equity stock holder, and a board of director member, of BioClassifier LLC and University Genomics. CMP is also listed as an inventor on a patent application on the PAM50 molecular assay. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.